(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 6.33% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Merck & Co's revenue in 2024 is $61,402,000,000.On average, 6 Wall Street analysts forecast MRK's revenue for 2024 to be $162,801,494,931,796, with the lowest MRK revenue forecast at $160,804,047,893,906, and the highest MRK revenue forecast at $164,633,093,812,703. On average, 7 Wall Street analysts forecast MRK's revenue for 2025 to be $174,277,455,413,952, with the lowest MRK revenue forecast at $168,294,467,953,976, and the highest MRK revenue forecast at $182,151,831,180,519.
In 2026, MRK is forecast to generate $187,201,682,140,871 in revenue, with the lowest revenue forecast at $175,842,762,638,160 and the highest revenue forecast at $204,113,794,668,516.